Skip to main content
Clinical Trials/NCT01081210
NCT01081210
Completed
Not Applicable

Screening With Pocket-sized Ultrasound of Patients Admitted to Department of Medicine at a Local Hospital

Helse Nord-Trøndelag HF2 sites in 1 country400 target enrollmentMarch 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Disease
Sponsor
Helse Nord-Trøndelag HF
Enrollment
400
Locations
2
Primary Endpoint
Diagnostic sensitivity and specificity
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Ultrasound (US) is widely used as a diagnostic tool in a hospital setting. In a medical department, diagnosis like heart failure or most kinds of heart diseases, hypervolemia, hypovolemia, pleural effusion, pericardial effusion, ascites, diseases in the gall bladder/bile tract, urine tract and venous thrombosis are common. US is the key diagnostic tool in these diagnosis, and on early diagnosis is crucial both on behalf of the patients well-being, and for hospital logistic reasons.

  1. The aim is to study the clinical use of pocket sized US as a screening diagnostic tool in an department of internal medicine.

    Method: All patients admitted (in certain preset periods) to Department of medicine will be screened with pocket sized US by expert user. Changes in diagnoses, as well as medications as a result of US screening will be the endpoints. US findings will be validated against standard echocardiography, or standard US/CT/MRI performed at the Radiological department.

  2. The aim is to study the clinical use of pocket sized US as a screening diagnostic tool in a department of cardiology.

    Method: All patients admitted (in certain preset periods) to Department of cardiology will be screened with pocket sized US for heart disease, pericardial and pleural effusion. Examinations by expert users. Specific findings could be myocardial dysfunction as heart failure, cardiomyopathies, regional dysfunction due to ischemia, valvular dysfunction, atrial enlargement, and pleural/pericardial effusion. Changes in diagnoses, as well as medications as a result of US screening will be the endpoints. US findings will be validated against standard echocardiography in all.

  3. As in 1), but examination by non-expert users compared to expert users.

Registry
clinicaltrials.gov
Start Date
March 2010
End Date
October 2010
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients admitted to Dep. of Medicine at Levanger Hospital

Exclusion Criteria

  • Not able to give informed consent

Outcomes

Primary Outcomes

Diagnostic sensitivity and specificity

Time Frame: After 3-6 months

Diagnostic accuracy and clinical usefulness of ultrasound screening as add on examination. Change in working diagnosis after ultrasound examination will be tested, and gold standards (echocardiography and examinations at Department of radiology) will be used for testing of sensitivity and specificity.

Secondary Outcomes

  • Non-experts(After 3-6 months)

Study Sites (2)

Loading locations...

Similar Trials